ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTMX CytomX Therapeutics Inc

1.67
-0.06 (-3.47%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 505,550
Bid Price 1.67
Ask Price 1.85
News -
Day High 1.75

Low
1.04

52 Week Range

High
2.855

Day Low 1.635
Company Name Stock Ticker Symbol Market Type
CytomX Therapeutics Inc CTMX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -3.47% 1.67 17:28:41
Open Price Low Price High Price Close Price Prev Close
1.72 1.635 1.75 1.67 1.73
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,635 505,550 $ 1.69 $ 852,668 - 1.04 - 2.855
Last Trade Time Type Quantity Stock Price Currency
16:17:45 formt 11,629 $ 1.67 USD

CytomX Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
113.1M 67.72M - 101.21M -569k -0.01 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CytomX Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CTMX Message Board. Create One! See More Posts on CTMX Message Board See More Message Board Posts

Historical CTMX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.142.261.6351.96472,628-0.47-21.96%
1 Month2.212.301.6352.10670,570-0.54-24.43%
3 Months1.542.8551.412.27968,4450.138.44%
6 Months1.352.8551.042.06608,5920.3223.70%
1 Year1.652.8551.041.93448,4310.021.21%
3 Years7.4110.051.043.001,015,822-5.74-77.46%
5 Years9.5115.441.044.32822,368-7.84-82.44%

CytomX Therapeutics Description

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.

Your Recent History

Delayed Upgrade Clock